Review



bcva  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc bcva
    Bcva, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pm41927600-103-13-21?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    bcva - by Bioz Stars, 2026-07
    86/100 stars

    Images



    Similar Products

    acuity bcva  (Kowa Company)
    86
    Kowa Company acuity bcva
    Acuity Bcva, supplied by Kowa Company, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pmc13160835-88-17-24?v=Kowa+Company
    Average 86 stars, based on 1 article reviews
    acuity bcva - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    bcva  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc bcva
    Bcva, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pm41927600-103-13-21?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    bcva - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    acuity bcva  (Precision Vision)
    86
    Precision Vision acuity bcva
    Acuity Bcva, supplied by Precision Vision, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pm41912321-23-6-16?v=Precision+Vision
    Average 86 stars, based on 1 article reviews
    acuity bcva - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    bcva  (Luminopia Inc)
    86
    Luminopia Inc bcva
    Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
    Bcva, supplied by Luminopia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pmc13123015-139-7-0?v=Luminopia+Inc
    Average 86 stars, based on 1 article reviews
    bcva - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    bcva gains  (Luminopia Inc)
    86
    Luminopia Inc bcva gains
    Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
    Bcva Gains, supplied by Luminopia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pmc13123015-108-0-4?v=Luminopia+Inc
    Average 86 stars, based on 1 article reviews
    bcva gains - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    luminopia improved bcva  (Luminopia Inc)
    86
    Luminopia Inc luminopia improved bcva
    Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
    Luminopia Improved Bcva, supplied by Luminopia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pmc13123015-161-1-1?v=Luminopia+Inc
    Average 86 stars, based on 1 article reviews
    luminopia improved bcva - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    bcva  (Precision Vision)
    86
    Precision Vision bcva
    Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
    Bcva, supplied by Precision Vision, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pm41839400-48-0-11?v=Precision+Vision
    Average 86 stars, based on 1 article reviews
    bcva - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    bcva change  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc bcva change
    Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
    Bcva Change, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/pm41712521-168-5-15?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    bcva change - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    non recurrent rd group id m f age eye bcva n  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health non recurrent rd group id m f age eye bcva n
    Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
    Non Recurrent Rd Group Id M F Age Eye Bcva N, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcva/10__1097_slash_iae__0000000000004777-281-6-2?v=Wolters+Kluwer+Health
    Average 86 stars, based on 1 article reviews
    non recurrent rd group id m f age eye bcva n - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

    Journal: BMC Ophthalmology

    Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

    doi: 10.1186/s12886-026-04747-3

    Figure Lengend Snippet: Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

    Article Snippet: Luminopia showed greater improvement in lines of BCVA compared to glasses alone after 12-weeks of treatment (1 h 6 days per week) [ , ].

    Techniques:

    BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

    Journal: BMC Ophthalmology

    Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

    doi: 10.1186/s12886-026-04747-3

    Figure Lengend Snippet: BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

    Article Snippet: Luminopia showed greater improvement in lines of BCVA compared to glasses alone after 12-weeks of treatment (1 h 6 days per week) [ , ].

    Techniques:

    Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

    Journal: BMC Ophthalmology

    Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

    doi: 10.1186/s12886-026-04747-3

    Figure Lengend Snippet: Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

    Article Snippet: BCVA gains achieved with Luminopia were maintained regardless of whether physicians recommended additional follow-up amblyopia treatment.

    Techniques:

    BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

    Journal: BMC Ophthalmology

    Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

    doi: 10.1186/s12886-026-04747-3

    Figure Lengend Snippet: BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

    Article Snippet: BCVA gains achieved with Luminopia were maintained regardless of whether physicians recommended additional follow-up amblyopia treatment.

    Techniques:

    Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

    Journal: BMC Ophthalmology

    Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

    doi: 10.1186/s12886-026-04747-3

    Figure Lengend Snippet: Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

    Article Snippet: While Luminopia improved BCVA in all subgroups, subgroup analysis identified which children received the greatest benefit.

    Techniques:

    BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

    Journal: BMC Ophthalmology

    Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

    doi: 10.1186/s12886-026-04747-3

    Figure Lengend Snippet: BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

    Article Snippet: While Luminopia improved BCVA in all subgroups, subgroup analysis identified which children received the greatest benefit.

    Techniques: